3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
CNS
2
Breast
2
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
9
Pancreatic Neoplasms
6
Ovarian Neoplasms
5
Sarcoma
4
Neuroblastoma
4
Liver Neoplasms
4
Wilms Tumor
3
Somatostatinoma
3
Rectal Neoplasms
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Neoplasms
3
Medulloblastoma
3
Gastrointestinal Stromal Tumors
3
Esophageal Neoplasms
3
Astrocytoma
3
Zollinger-Ellison Syndrome
2
Vipoma
2
Testicular Neoplasms
2
Teratoma
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Ovarian Germ Cell Cancer
2
Optic Nerve Glioma
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Melanoma
2
Interventions
pembrolizumab
17
Surveys and Questionnaires
12
Specimen Handling
11
Docetaxel
11
Nivolumab
9
Interviews as Topic
9
Standard of Care
8
Gemcitabine
8
Early Intervention, Educational
8
olaparib
7
enzalutamide
7
Magnetic Resonance Spectroscopy
7
Psychiatric Rehabilitation
6
Paclitaxel
6
durvalumab
5
Trastuzumab
5
Radiotherapy
5
Ipilimumab
5
Carboplatin
5
Bevacizumab
5
pertuzumab
4
palbociclib
4
cabozantinib
4
atezolizumab
4
abiraterone
4
Therapeutics
4
Taxes
4
Oxaliplatin
4
Methods
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Temozolomide
×
Gastrointestinal
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled